University of Southern California
USC Norris Comprehensive Cancer Center
If you are a patient, please contact Keck Medical Center of USC at 800-USC-CARE.

Trial Search: "GASTROINTESTINAL"



Treatment trials which apply specifically to your search:


0C-11-3

Trial Leaders:
Anthony El-Khoueiry

A First-In-Human Phase I Study of sEphB4-HSA in Patients with Advanced Solid Tumors with Expansion at the Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D).

Treatment:
Anti-Angiogenesis

0C-12-3

Trial Leaders:
Heinz Josef Lenz

Phase I Trial of Oral 5-Fluoro-2’-Deoxycytidine With Oral Tetrahydrouridine in Patients With Advanced Solid Tumors.

Treatment:
Chemotherapy: Systemic

0C-14-10

Trial Leaders:
Anthony El-Khoueiry

A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 under Adaptable Dosing Schedules in Patients with Advanced Solid Malignancies

Treatment:
Chemotherapy: Local

0C-14-11

Trial Leaders:
Anthony El-Khoueiry

A Phase 1, Open-Label, Dose Escalation Study of Pf-04518600 as a Single Agent and In Combination with PF-05082566 In Patients with Selected Locally Advanced or Metastatic Cancers

Treatment:
Chemotherapy: Systemic

0C-14-2

Trial Leaders:
David Quinn

An Open-Label, Phase 2 Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (Egfr, Her2, Her3) Mutations or EGFR Gene Amplification

Treatment:
Chemotherapy: Systemic

0C-14-9

Trial Leaders:
Anthony El-Khoueiry

A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD6738 in combination with Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients with Advanced Solid Malignancies

Treatment:
Chemotherapy: Systemic

0C-15-2

Trial Leaders:
Jorge Nieva

STARTRK-2 (Studies of Tumor Alterations Responsive to Targeting Receptor Kinases-2) An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Treatment:
Chemotherapy: Systemic

0C-15-3

Trial Leaders:
Anthony El-Khoueiry

PhI-76 Phase I Study of TRC102 in Combination with Cisplatin and Pemetrexed in Patients with Advanced Solid Tumors, with Expansion Cohort in Mesothelioma / Phase II Study of TRC102 with Pemetrexed in Patients Refractory to Cisplatin and Pemetrexed

Treatment:
Chemotherapy: Systemic

0C-15-5

Trial Leaders:
Anthony El-Khoueiry

A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158)

Treatment:
Chemotherapy: Systemic

0C-16-3

Trial Leaders:
Heinz Josef Lenz

An Open-Label, Non-Randomized, Multicenter Phase I Study to Determine the Maximum Tolerated or Recommended Phase II Dose of Oral Mutant IDH1 Inhibitor BAY 1436032 and to Characterize its Safety, Tolerability, Pharmacokinetics and Preliminary Pharmacodynamic and Anti-Tumor Activity in Patients with IDH1-R132X-Mutant Advanced Solid Tumors

Treatment:
Chemotherapy: Systemic

0C-16-6

Trial Leaders:
Anthony El-Khoueiry

PhI-87 Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors

Treatment:
Chemotherapy: Systemic

0C-16-7

Trial Leaders:
Anthony El-Khoueiry

An Open-label, Dose-finding and Proof of Concept Study for Probody™ therapeutics (probody tx) in Subjects with Metastatic or Locally Advanced Unresectable Solid Tumors and/or Lymphomas

Treatment:
Immunotherapy
Other

0C-16-8

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects with Advanced Refractory Cancers

Treatment:
Chemotherapy: Local

0C-17-1

Trial Leaders:
Anthony El-Khoueiry

Phase 1 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of CBT-101 in Subjects with Advanced Solid Tumors and c-Met Dysregulation

Treatment:
Other

0C-17-11

Trial Leaders:
Diana Hanna

Phase 1 trial of ZW25 in patients with locally advanced (unresectable) and/or metastatic HER2-expressing cancers

Treatment:
Other

0C-17-12

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2a Study of BMS-986242 Administered in Combination with Nivolumab (BMS--936558, Anti-PD-1) in Advanced Malignant Tumors

Treatment:
Immunotherapy

0C-17-14

Trial Leaders:
Anthony El-Khoueiry

An Open-Label, Non-Randomized, Multicenter Study to Determine the Pharmacokinetics and Safety of Niraparib Following a Single Oral Dose in Patients with Advanced Solid Tumors and Either Normal Hepatic Function or Moderate Hepatic Impairment

Treatment:
Chemotherapy: Systemic

0C-17-15

Trial Leaders:
Anthony El-Khoueiry

A multicenter, open-label, phase 1b/2 study to evaluate safety and efficacy of avelumab (MSB0010718C) in combination with chemotherapy with or without other anti-cancer immunotherapies as first-line treatment in patients with advanced malignancies

Treatment:
Chemotherapy: Systemic

0C-17-17

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2 First-in-human Study of BMS-986258 Alone and in Combination with Nivolumab in Advanced Malignant Tumors

Treatment:
Immunotherapy

0C-17-3

Trial Leaders:
Anthony El-Khoueiry

A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors

Treatment:
Chemotherapy: Systemic

0C-17-4

Trial Leaders:
Anthony El-Khoueiry

Phase 1b multi-indication study of anetumab ravtansine (BAY 94-9343) in patients with mesothelin expressing advanced or recurrent malignancies

Treatment:
Biological Response Modifier

0C-17-5

Trial Leaders:
Heinz Josef Lenz

A Phase 1b/2 Study of BMS-813160 in Combination with Chemotherapy or Nivolumab in Patients with Advanced Solid Tumors

Treatment:
Biological Response Modifier
Chemotherapy: Systemic

0S-08-9

Trial Leaders:
David Quinn

Short-Term Fasting Prior to Platinum-Based Chemotherapy: Feasibility and Impact on Toxicity.

Treatment:
Chemotherapy: Systemic

0S-10-3

Trial Leaders:
David Quinn

A Randomized, Phase II Clinical Trial of a Controlled Diet Prior to Selected Chemotherapy Treatment in Breast and Prostate Cancer to Evaluate the Impact on Toxicity and Efficacy.

Treatment:
Other

0S-14-3

Trial Leaders:
Syma Iqbal

Phase II Study of Single Agent Regorafenib in Patients with Advanced/Metastatic Neuroendocrine Tumors

Treatment:
Chemotherapy: Systemic

0S-14-8

Trial Leaders:
Howard Liebman

Randomized, Placebo-Controlled, Double-Blind Phase II/III Trial of Oral Isoquercetin to Prevent Venous Thromboembolic Events in Cancer Patients

Treatment:
Other

0S-14-9

Trial Leaders:
Heinz Josef Lenz

A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination with Nivolumab in Select Advanced Cancers

Treatment:
Chemotherapy: Systemic
Immunotherapy

0S-15-11

Trial Leaders:
David Quinn

PhI-81 A Phase 1 Study of (Cabozantinib) plus Nivolumab (CaboNivo) Alone or in Combination with Ipilimumab (CaboNivoIpi) in Patients with Advanced/Metastatic Urothelial Carcinoma and other Genitourinary Tumors

Treatment:
Other

0S-15-5

Trial Leaders:
Anthony El-Khoueiry

A Pilot Multi-Arm Study of sEphB4-HSA In Combination with Different Chemotherapy Regimens in Patients with Specific Advanced or Metastatic Solid Tumors

Treatment:
Chemotherapy: Systemic

0S-15-6

Trial Leaders:
David Quinn

A Pilot Study of Neoadjuvant sEphB4-HSA in Patients with Genitourinary Cancers

Treatment:
Anti-Angiogenesis

0S-16-12

Trial Leaders:
David Quinn

A Multicenter Phase II Study of Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors

Treatment:
(No treatments specified)

0S-16-13

Trial Leaders:
David Quinn

A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

Treatment:
Chemotherapy: Systemic

0S-16-14

Trial Leaders:
David Quinn

A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial Cancer and Other Malignant Solid Tumors that Express Nectin-4

Treatment:
Biological Response Modifier

0S-16-15

Trial Leaders:
Ann Mohrbacher

Phase Ib Trial of Pembrolizumab (MK-3475) in Combination with Dinaciclib (MK-7965) in Subjects with Hematologic Malignancies (KEYNOTE-155)

Treatment:
Biological Response Modifier

0S-16-18

Trial Leaders:
Anthony El-Khoueiry

A Phase Ib Study of Guadecitabine (SGI-110) and Durvalumab (MEDI 4736) in Patients with Advanced Hepatocellular Carcinoma, Pancreatic Adenocarcinoma, and Cholangiocarcinoma/Gallbladder Cancer

Treatment:
Chemotherapy: Systemic
Other

0S-16-3

Trial Leaders:
David Quinn

A Phase I/Ib, Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab (MK-3475) in Combination with Vorinostat in Patients with Advanced Renal or Urothelial Cell Carcinoma

Treatment:
Chemotherapy: Systemic

0S-16-8

Trial Leaders:
Jorge Nieva

A Phase IIa Trial of sEphB4-HSA in Combination with Anti PD-1 Antibody (Pembrolizumab, MK3475) in Patients with Non-Small Cell Lung and Head/Neck Cancer

Treatment:
Chemotherapy: Systemic

0S-17-3

Trial Leaders:
Julie Lang

Phase 2a Dose-Rising, Safety, Tolerability and Efficacy Study of Topical SOR007 for Cutaneous Metastases

Treatment:
Chemotherapy: Local

0S-17-5

Trial Leaders:
Christina M. Dieli-Conwright

Circuit, interval-based Aerobic and Resistance Exercise to Target Metabolic Dysregulation: The CARE Study for Breast and Prostate Cancer Survivors

Treatment:
Other

0S-17-6

Trial Leaders:
Heinz Josef Lenz

PhII-155 A Phase 2 Study of MEDI4736(Durvalumab) and Tremelimumab Alone or in Combination with High or Low-Dose Radiation in Metastatic Colorectal and NSCLC

Treatment:
Biological Response Modifier

0S-17-8

Trial Leaders:
Gino In

PhII-159 A Phase II Study of Talimogene laherparepvec Followed by Talimogene laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors

Treatment:
Immunotherapy

10M-17-2

Trial Leaders:
Gino In

A phase III, open-label, multicenter, two arm, randomized study to investigate the efficacy and safety of cobimetinib plus atezolizumab versus pembrolizumab in patients with previously untreated advanced BRAFv600 wild-type melanoma

Treatment:
Immunotherapy

11S-15-1

Trial Leaders:
James Hu

SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients with Advanced Sarcomas

Treatment:
Biological Response Modifier

11S-17-1

Trial Leaders:
James Hu

PhII-148 A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma

Treatment:
Biological Response Modifier

13NHL-15-2

Trial Leaders:
Ann Mohrbacher

Phase II Trial of Intravenous Fenretinide (N-(4-hydroxyphenyl) retinamide, 4-HPR) Emulsion for Patients with Relapsed/Refractory Peripheral T-cell Lymphomas (PTCL)

Treatment:
Chemotherapy: Systemic

13NHL-16-3

Trial Leaders:
Mojtaba Akhtari

PhI-79 A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients with Relapsed or Refractory Non-Hodgkins Lymphoma (NHL)

Treatment:
(No treatments specified)

13NHL-16-4

Trial Leaders:
Ann Mohrbacher

An Open-Label Phase 1/2 Study of INCB039110 in Combination with Ibrutinib in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Treatment:
Other

13NHL-17-1

Trial Leaders:
Kevin Kelly

A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/ Refractory Indolent Non-Hodgkin Lymphoma (INHL)

Treatment:
Chemotherapy: Systemic
Other

1B-10-3

Trial Leaders:
Julie Lang

Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2.

Treatment:
Chemotherapy: Systemic

1B-13-1

Trial Leaders:
Min Janice Lu

A Phase II Study of Neratinib Alone and in Combination with Fulvestrant in Metastatic HER2 Non-amplified but HER2 Mutant Breast Cancer

Treatment:
Chemotherapy: Systemic

1B-14-5

Trial Leaders:
Christina M. Dieli-Conwright

High-intensity Interval training (HIT) for Breast Cancer Patients during Trastuzumab or Anthracycline Use

Treatment:
Other

1B-15-2

Trial Leaders:
Min Janice Lu

A Phase II Randomized, Double-Blind, Placebo-Controlled Trial of Radium-223 Dichloride in Combination with Exemestane and Everolimus versus Placebo in Combination with Exemestane and Everolimus when Administered to Metastatic HER2 Negative Hormone Receptor Positive Breast Cancer Subjects with Bone Metastases

Treatment:
Biological Response Modifier
Radiation: Other

1B-16-8

Trial Leaders:
Min Janice Lu

Phase 1b Study to Assess the Safety, Tolerability, and Clinical Activity of Gedatolisib in Combination with Palbociclib and Either Letrozole or Fulvestrant in Women with Metastatic or Locally Advanced/Recurrent Breast Cancer (MBC)

Treatment:
Hormone
Other

1B-17-4

Trial Leaders:
Min Janice Lu

A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer – (KEYNOTE-355)

Treatment:
Chemotherapy: Systemic
Other

1B-17-7

Trial Leaders:
Julie Lang

A large scale multicenter phase 2 study evaluating the protective effect of a tissue selective estrogen complex (TSEC) in women with newly diagnosed ductal carcinoma in situ

Treatment:
Hormone

2N-13-6

Trial Leaders:
Jorge Nieva

A Randomized Phase II Study of Epigenetic Priming with Azacitidine and Entinostat Prior to Nivolumab versus Nivolumab Alone in Subjects with Recurrent Metastatic Non-Small Cell Lung Cancer

Treatment:
Chemotherapy: Systemic

2N-15-6

Trial Leaders:
Jorge Nieva

Phase I/II, First-in-Human, Dose-Escalation Study of X-396 in Patients with Advanced Solid Tumors and Expansion Phase in Patients with ALK+ Non-Small Cell Lung Cancer

Treatment:
Chemotherapy: Local

2N-16-2

Trial Leaders:
Jorge Nieva

PhI-80 A Phase 1/2 Trial of Erlotinib and Onalespib lactate in EGFR-Mutant Non-Small Cell Lung Cancer

Treatment:
Other

2N-16-3

Trial Leaders:
Jorge Nieva

A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-Oncology Study in Subjects with Advanced Non-small Cell Lung Cancer (FRACTION-Lung)

Treatment:
Immunotherapy

2N-16-4

Trial Leaders:
Jorge Nieva

A Multi-Center Open-Label Phase 1/2 Study of BGB324 in Combination with Erlotinib in Patients with Stage IIIb or Stage IV Non-Small Cell Lung Cancer

Treatment:
Other

2N-16-6

Trial Leaders:
Diana Hanna

A Phase 1b Study of the Selective HDAC6 Inhibitor ACY-241 in Combination With Nivolumab in Patients With Unresectable Non-Small Cell Lung Cancer

Treatment:
Chemotherapy: Systemic
Immunotherapy

2N-16-9

Trial Leaders:
Thomas Chen

Pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 brain metastases from non-small cell lung cancer (NSCLC)

Treatment:
Other

2O-17-1

Trial Leaders:
Jorge Nieva

PhII-151 A Phase II Study of Olaparib plus Cediranib in Combination with Standard Therapy for Small Cell Lung Cancer

Treatment:
Anti-Angiogenesis
Chemotherapy: Systemic

3BD-17-1

Trial Leaders:
Anthony El-Khoueiry

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation

Treatment:
Chemotherapy: Systemic

3C-13-8

Trial Leaders:
Anthony El-Khoueiry

A phase I study of SGI-110 combined with irinotecan followed by a randomized phase II study of SGI-110 combined with irinotecan versus regorafenib in previously treated metastatic colorectal cancer patients

Treatment:
Chemotherapy: Systemic

3C-14-1

Trial Leaders:
Heinz Josef Lenz

A Phase 2 Clinical Trial of Nivolumab or Nivolumab Combinations in Recurrent and Metastatic Microsatellite Instability High (MSI-H) and non-MSI-H Colon Cancer

Treatment:
Chemotherapy: Systemic

3C-16-5

Trial Leaders:
Heinz Josef Lenz

The BEACON CRC Study (Binimetinib, Encorafenib, And Cetuximab COmbiNed to Treat BRAF-mutant ColoRectal Cancer): A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA) /Irinotecan (FOLFIRI)/Cetuximab with a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients with BRAF V600E-mutant Metastatic Colorectal Cancer

Treatment:
Biological Response Modifier
Chemotherapy: Systemic

3C-16-6

Trial Leaders:
Afsaneh Barzi

Randomized Phase III Trial of 5-FU Based Maintenance Therapy with or without Panitumumab in Patients with RAS WT Metastatic Colorectal Cancer after Induction with FOLFOX + Panitumumab

Treatment:
Chemotherapy: Systemic
Other

3C-17-1

Trial Leaders:
Heinz Josef Lenz

A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC).

Treatment:
Biological Response Modifier
Chemotherapy: Systemic

3C-17-2

Trial Leaders:
Heinz Josef Lenz

BACCI: A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Capecitabine Bevacizumab plus Atezolizumab versus Capecitabine Bevacizumab plus Placebo in Patients with Refractory Metastatic Colorectal Cancer

Treatment:
Chemotherapy: Systemic

3C-17-4

Trial Leaders:
Heinz Josef Lenz

An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer

Treatment:
Chemotherapy: Systemic
Immunotherapy

3G-15-2

Trial Leaders:
Heinz Josef Lenz

A Phase 1b/2 Study of MEDI4736 in Combination with Tremelimumab, MEDI4736 Monotherapy, and Tremelimumab Monotherapy in Subjects with Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma

Treatment:
Immunotherapy

3G-16-3

Trial Leaders:
Heinz Josef Lenz

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Treatment:
Immunotherapy

3G-16-4

Trial Leaders:
Syma Iqbal

A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab versus Oxaliplatin plus Fluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

Treatment:
Chemotherapy: Systemic

3G-17-2

Trial Leaders:
Syma Iqbal

A Phase Ib/II, open-label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-based Treatment Combinations in Patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction cancer (morpheus-gastric cancer)

Treatment:
Biological Response Modifier
Chemotherapy: Systemic
Immunotherapy

3GB-14-1

Trial Leaders:
Anthony El-Khoueiry

A phase II multicenter, single arm study of oral BGJ398 in adult patients with advanced or metastatic cholangiocarcinoma with FGFR2 gene fusions or other FGFR genetic alterations who failed or are intolerant to platinum-based chemotherapy

Treatment:
Chemotherapy: Systemic

3L-14-1

Trial Leaders:
Michael Katz

Surefire vs. Endhole for DEB-TACE: Quantifying Hepatic Artery Embolization to Improve Outcomes (A Comparison of Two Different Catheter Systems for DEB-TACE)

Treatment:
Other

3L-16-4

Trial Leaders:
Anthony El-Khoueiry

A Phase Ib/II Clinical Study of BBI608 in Combination with Sorafenib or BBI503 in Combination with Sorafenib in Adult Patients with Hepatocellular Carcinoma

Treatment:
(No treatments specified)

3L-17-1

Trial Leaders:
Anthony El-Khoueiry

A Phase I Open Label, Clinical Trial Evaluating the Safety and Anti-Tumor Activity of Autologous T Cells Expressing Enhanced TCRS Specific for Alpha Fetoprotein (AFPC332T) in HLA-A2 Positive Subjects with Advanced Hepatocellular Carcinoma (HCC)

Treatment:
Other

3P-16-3

Trial Leaders:
Jaques Van Dam

Phase IIa Trial Evaluating the Safety of Intratumoral Injection of NanoPac in Subjects with Locally Advanced Pancreatic Adenocarcinoma

Treatment:
Other

3P-17-2

Trial Leaders:
Heinz Josef Lenz

A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen

Treatment:
Biological Response Modifier
Chemotherapy: Systemic

4B-14-2

Trial Leaders:
Hooman Djaladat

Prevention of parastomal hernia following radical cystectomy and ileal conduit using biologic mesh: Randomized Clinical Trial

Treatment:
Other

4B-15-11

Trial Leaders:
Sarmad Sadeghi

A Phase II Trial of sEphB4-HSA in Combination with Anti PD1 Antibody (Pembrolizumab, MK-7435) for Metastatic Urothelial Cancer Refractory to Platinum

Treatment:
Immunotherapy

4B-15-12

Trial Leaders:
David Quinn

A Phase III, Open-Label, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) versus Observation as Adjuvant Therapy in Patients with High-Risk Muscle-Invasive Urothelial Carcinoma After Surgical Resection

Treatment:
Immunotherapy

4B-15-14

Trial Leaders:
Siamak Daneshmand

A Phase lb, Multicenter, Open Label Study Evaluating Safety, Tolerability and Preliminary Efficacy of GemRIS 225 mg in Subjects with Muscle-Invasive Transitional Cell Carcinoma of the Bladder

Treatment:
Chemotherapy: Local
Surgery

4B-15-15

Trial Leaders:
David Quinn

An Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Multi-Centre, Multi-arm Phase 1b Study in Patients with Muscle Invasive Bladder Cancer (MIBC) Who have Progressed on Prior Treatment (BISCAY)

Treatment:
Immunotherapy

4B-15-4

Trial Leaders:
Mihir Desai

Prospective Randomized Comparison Of Robotic Versus Open Radical Cystectomy

Treatment:
Surgery

4B-16-4

Trial Leaders:
David Quinn

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer (GU14-182)

Treatment:
(No treatments specified)

4B-16-5

Trial Leaders:
Anne Schuckman

A Phase III, Open Label Study to Evaluate the Safety and Efficacy of INSTILADRIN(I> (rAd-IFN/Syn3) Administered lntravesically to Patients with High Grade, BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)

Treatment:
Chemotherapy: Local

4B-16-6

Trial Leaders:
Sarmad Sadeghi

Ph II-135 A Randomized Phase 2 Trial of Cisplatin/Gemcitabine with or without VX-970 in Metastatic Urothelial Carcinoma

Treatment:
Chemotherapy: Systemic

4B-16-8

Trial Leaders:
David Quinn

PH II-147 An Open Label, Multicenter, Single arm Phase II study to evaluate the Activity and Tolerability of the novel mTOR Inhibitor, MLN0128 (TAK-228), in patients with Locally Advanced or Metastatic Transitional Cell Carcinoma of the urothelial tract whose tumors harbor a TSC1 and/or a TSC2 mutation.

Treatment:
Chemotherapy: Systemic
Other

4B-17-1

Trial Leaders:
David Quinn

A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma

Treatment:
Biological Response Modifier
Chemotherapy: Systemic

4B-17-2

Trial Leaders:
David Quinn

A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy

Treatment:
Biological Response Modifier

4K-16-2

Trial Leaders:
David Quinn

A Multi-center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma

Treatment:
Immunotherapy

4K-16-3

Trial Leaders:
Sarmad Sadeghi

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared with Everolimus in the Treatment of Adult Patients with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma that Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Treatment:
(No treatments specified)

4K-16-4

Trial Leaders:
David Quinn

A Phase I Open-Label, Dose Escalation and Cohort Expansion Study, to assess the Safety and Activity of the Antibody-Drug Conjugate CDX-014 in Advanced or Metastatic Renal Cell Carcinoma (RCC) and Advanced or Metastatic Ovarian Clear Cell Carcinoma (OCCC)

Treatment:
Other

4K-16-5

Trial Leaders:
Sarmad Sadeghi

Phase II Randomized Double Blind Trial of PF 04518600, an OX40 Antibody, in Combination with Axitinib versus Axitinib in Immune-Checkpoint Inhibitor Exposed Patients with Metastatic Renal Cell Carcinoma

Treatment:
Immunotherapy

4K-17-1

Trial Leaders:
David Quinn

A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)

Treatment:
Other

4P-14-1

Trial Leaders:
Mitchell Gross

Phase 2 Trial of Phenelzine in Non-Metastatic Recurrent Prostate Cancer

Treatment:
Chemotherapy: Systemic

4P-14-10

Trial Leaders:
David Quinn

A Phase I, Open-Label, Dose-Finding Study of GSK2636771 Administered in Combination with Enzalutamide (Xtandi) in Male Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Treatment:
Chemotherapy: Systemic

4P-14-8

Trial Leaders:
Leslie Ballas

Phase I dose-escalation study of SBRT for adjuvant/salvage radiotherapy in prostate cancer

Treatment:
Radiation: Other

4P-16-8

Trial Leaders:
Inderbir Gill

Phase IIa Dose Escalation Trial of NanoPac Focal Therapy for Prostate Cancer in Subjects Undergoing Radical Prostatectomy

Treatment:
(No treatments specified)

4P-17-2

Trial Leaders:
Mitchell Gross

TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency

Treatment:
(No treatments specified)

4P-17-3

Trial Leaders:
Mitchell Gross

TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician’s Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency

Treatment:
Hormone
Other

4P-17-5

Trial Leaders:
David Quinn

A phase III, randomized, double-blind, placebo-controlled, multicenter trial testing Ipatasertib plus Abiraterone plus Prednisone/Prednisolone, relative to Placebo plus Abiraterone plus Prednisone/prednisolone in adult male patients with asymptomatic or mildly symptomatic, previously untreated, metastatic castrate-resistant prostate cancer

Treatment:
Hormone
Other

4P-17-6

Trial Leaders:
Mitchell Gross

A phase IB open-label, dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with androgen deprivation therapy and other agents in subjects with castrateresistant prostate cancer (CRPC)

Treatment:
Other

4PE-15-1

Trial Leaders:
David Quinn

A phase 2 trial using Gilotrif for Advanced Penile Squamous Cell Carcinoma following systemic therapy.

Treatment:
Immunotherapy

4PE-16-1

Trial Leaders:
David Quinn

Phase II Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma following Previous Chemotherapy

Treatment:
Other

4T-14-1

Trial Leaders:
Siamak Daneshmand

Surgery in Early Metastatic Seminoma (SEMS): Phase II Trial of Retroperitoneal Lymph Node Dissection as First-Line Treatment For Testicular Seminoma with Isolated Retroperitoneal Disease (1-3cm)

Treatment:
Surgery

5C-11-2

Trial Leaders:
Lynda Roman

Phase II Clinical Trial of Eribulin in Advanced or Recurrent Cervical Cancer.

Treatment:
Chemotherapy: Systemic

5C-17-2

Trial Leaders:
Koji Matsuo

A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic or Persistent Cervical Carcinoma

Treatment:
Chemotherapy: Systemic
Immunotherapy
Other

5GYN-15-1

Trial Leaders:
Koji Matsuo

A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb-003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer

Treatment:
Chemotherapy: Systemic

5GYN-16-2

Trial Leaders:
Lynda Roman

A Two-Cohort Randomized Phase 2 Trial of the IRX 2 Regimen in Women with Squamous Cervical Intraepithelial Neoplasia 3 (CIN 3) or Vulvar Intraepithelial Neoplasia 3 (VIN 3)

Treatment:
Chemotherapy: Systemic

5U-16-1

Trial Leaders:
Christina M. Dieli-Conwright

Endometrial Cancer and Obesity: An Exercise and Diet Intervention for Weight Loss

Treatment:
Other

6B-15-1

Trial Leaders:
Thomas Chen

Pilot Trial of NovoTTF -200A (TTFields) in Patients with Newly Diagnosed High Risk Oligodendrogliomas

Treatment:
(No treatments specified)

6B-17-1

Trial Leaders:
Naveed Wagle

A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy STELLAR Study

Treatment:
Chemotherapy: Systemic
Other

6G-15-2

Trial Leaders:
Naveed Wagle

An Open-Label, Phase 1/2a Dose Escalation Study of Safety and Efficacy of NEO100 in Recurrent Grade IV Glioma

Treatment:
Other

7H-16-1

Trial Leaders:
Jorge Nieva

A Phase 1b/2, Open-Label, Multicenter Study Assessing the Safety, Tolerability, Pharmacokinetic and Preliminary Anti-tumour Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination With MEDI4736 as Second Line Treatment in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

Treatment:
Immunotherapy

9L-15-11

Trial Leaders:
Casey O'Connell

Clinical Study Protocol With Amendment 1 A Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Treatment:
Chemotherapy: Systemic

9L-15-12

Trial Leaders:
Kevin Kelly

A Phase Ib/II Multi-Arm Study with Venetoclax in Combination with Cobimetinib and Venetoclax in Combination with Idasanutlin in Patients Aged =60 Years with Relapsed or Refractory Acute Myeloid Leukemia who Are Not Eligible for Cytotoxic Therapy

Treatment:
Other

9L-15-5

Trial Leaders:
Akil Merchant

PhII-134, Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy

Treatment:
Immunomodulator

9L-16-13

Trial Leaders:
Mojtaba Akhtari

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the FLT3 Inhibitor Gilteritinib (ASP2215) Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects with FLT3/ITD AML in First Complete Remission

Treatment:
Other

9L-16-15

Trial Leaders:
Casey O'Connell

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination with Ruxolitinib in Subjects with Myelofibrosis

Treatment:
Chemotherapy: Systemic
Other

9L-16-17

Trial Leaders:
Casey O'Connell

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Treatment:
Other

9L-16-18

Trial Leaders:
Mojtaba Akhtari

PhII-145 A Phase 2 Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)

Treatment:
Anti-Angiogenesis

9L-16-3

Trial Leaders:
Casey O'Connell

A Phase I/II Multicenter Study Combining Guadecitabine, a DNA Methyltransferase Inhibitor, with Atezolizumab, an Immune Checkpoint Inhibitor, in Patients with Intermediate or High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Treatment:
Other

9L-16-6

Trial Leaders:
Casey O'Connell

A Pilot/Safety Study of sEphB4-HSA in Combination with a Hypomethylating Agent (HMA) for Patients with Relapsed or Refractory Myelodysplastic Syndrome (MDS) and AML Previously Treated with a Hypomethylating Agent

Treatment:
Other

9L-16-9

Trial Leaders:
Mojtaba Akhtari

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Treatment:
Chemotherapy: Systemic

9L-17-13

Trial Leaders:
Kevin Kelly

PhI-92: (NCI 10075) A Phase 1B Study of AMG-232 in Combination with Decitabine in Acute Myeloid Leukemia

Treatment:
Chemotherapy: Systemic

9L-17-3

Trial Leaders:
Mojtaba Akhtari

An Open-Label, Non-Randomized, Multicenter Phase I Study to Determine The Maximum Tolerated and /or Recommended Phase II Dose of Oral Mutant IDH1 (mIDH1) Inhibitor BAY 1436032 and to Characterize its Safety, tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Efficacy in Patients with mIDH1-R132X Advanced Acute Myeloid Leukemia (AML)

Treatment:
Chemotherapy: Systemic
Other

9L-17-6

Trial Leaders:
Kevin Kelly

Phase 1b/II Study of Escalating Doses of Pevonedistat (Tak-924, Formerly Mln4924) Administered in Combination with Standard Induction Chemotherapy (Cytarabine and Idarubicin) in Newly Diagnosed High Risk Acute Myelogenous Leukemia (AML)

Treatment:
Chemotherapy: Systemic

9L-17-7

Trial Leaders:
George Yaghmour

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease

Treatment:
Biological Response Modifier
Other

CTSU- A021502

Trial Leaders:
Heinz Josef Lenz

Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair

Treatment:
Chemotherapy: Systemic

CTSU-A031102

Trial Leaders:
James Hu

A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy using Mobilizing Paclitaxel plus Ifosfamide followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors

Treatment:
Chemotherapy: Systemic

CTSU-A071102

Trial Leaders:
Naveed Wagle

A Phase II/III Randomized Trial Of Veliparib Or Placebo In Combination With Adjuvant Temozolomide In Newly Diagnosed Glioblastoma with Mgmt Promoter Hypermethylation

Treatment:
Chemotherapy: Systemic

CTSU-A081105

Trial Leaders:
Jorge Nieva

Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

Treatment:
Chemotherapy: Systemic

CTSU-A091304

Trial Leaders:
James Hu

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in patients with Locally advanced/unresectable and/or metastatic Sarcoma

Treatment:
Other

CTSU-A211102

Trial Leaders:
Julie Lang

Testing for Atypia in Random Periareolar Fine Needle Aspiration (Rpfna) Cytology after 12 Months Metformin (1, 1-Dimethylbiguanide Hydrochloride) Chemoprevention versus Placebo Control in Premenopausal Women

Treatment:
Other

CTSU-E4512

Trial Leaders:
Jorge Nieva

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Treatment:
Chemotherapy: Systemic

CTSU-EA2142

Trial Leaders:
Syma Iqbal

Randomized Phase II Study of Cisplatin and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas

Treatment:
Chemotherapy: Systemic

CTSU-EAY131

Trial Leaders:
Heinz Josef Lenz

Molecular Analysis for Therapy Choice (MATCH)

Treatment:
(No treatments specified)

CTSU-N1048

Trial Leaders:
Afsaneh Barzi

A Phase II/III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision (PROSPECT)

Treatment:
Chemotherapy: Systemic

CTSU/A021501

Trial Leaders:
Syma Iqbal

Preoperative Extended Chemotherapy vs. Chemotherapy plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas

Treatment:
Chemotherapy: Systemic
Other

ctsu/CALGB-A011202

Trial Leaders:
Julie Lang

A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (CT1-3 N1) who Have Positive Sentinel Lymph Node Disease after Neoadjuvant Chemotherapy

Treatment:
Radiation: External
Surgery

CTSU/COG-NRG ARST1321

Trial Leaders:
James Hu

Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib

Treatment:
Radiation: External

CTSU/EA8143

Trial Leaders:
Jacek Pinski

A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)

Treatment:
Immunotherapy

CTSU/NRG-BR002

Trial Leaders:
Jason Ye

A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer

Treatment:
Biological Response Modifier
Chemotherapy: Systemic
Hormone
Radiation: External
Surgery

CTSU/NRG-BR003

Trial Leaders:
Min Janice Lu

A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

Treatment:
Chemotherapy: Systemic

CTSU/NRG-LU002

Trial Leaders:
Jason Ye

Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial

Treatment:
Radiation: External

ctsu/NSABP-51/RTOG1304

Trial Leaders:
Naomi Schechter

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

Treatment:
Radiation: External

CTSU/NSABP-B-55

Trial Leaders:
Min Janice Lu

A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy

Treatment:
Other

ctsu/RTOG0848

Trial Leaders:
Syma Iqbal

A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma.

Treatment:
Chemotherapy: Systemic
Radiation: External

CTSU/RTOG1112

Trial Leaders:
Anthony El-Khoueiry

Randomized Phase III Study of Sorafenib versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma

Treatment:
Chemotherapy: Systemic
Radiation: External

GOG-0225

Trial Leaders:
Koji Matsuo

Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Progression-Free Survival?

Treatment:
(No treatments specified)

NC-HEM-17-3

Trial Leaders:
Ilene Weitz

A Multicenter, Open-Label, Uncontrolled, Extension Study of RA101495 in Subjects with Paroxysmal Nocturnal Hemoglobinuria Who Have Completed a RA101495 Clinical Study

Treatment:
Other

NRG-BN001

Trial Leaders:
Richard Jennelle

Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma

Treatment:
Chemotherapy: Systemic
Radiation: External

NRG-BN003

Trial Leaders:
Eric Chang

Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma

Treatment:
Other

NRG-GU003

Trial Leaders:
Leslie Ballas

A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)

Treatment:
Hormone
Radiation: External

NRG-GY006

Trial Leaders:
Omar M  Ragab

A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer.

Treatment:
Chemotherapy: Systemic
Radiation: External

RTOG-0924

Trial Leaders:
Leslie Ballas

Androgen Deprivation Therapy and High Dose Radiotherapy with or without Whole-Pelvic Radiotherapy In Unfavorable Intermediate Or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

Treatment:
Radiation: External

RTOG-1008

Trial Leaders:
Richard Jennelle

A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors.

Treatment:
Chemotherapy: Systemic
Radiation: External

SWOG-S0820

Trial Leaders:
Syma Iqbal

A Double-Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer or Rectal Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES).

Treatment:
Other

SWOG-S1207

Trial Leaders:
Darcy Spicer

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer.

Treatment:
Chemotherapy: Systemic
Hormone

SWOG-S1418-BR006

Trial Leaders:
Min Janice Lu

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy.

Treatment:
(No treatments specified)

SWOG-S1500

Trial Leaders:
David Quinn

A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma

Treatment:
Other

SWOG-S1512

Trial Leaders:
Gino In

A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unsectable Desmoplastic Melanoma (DM)

Treatment:
Other

SWOG-S1602

Trial Leaders:
Siamak Daneshmand

A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Naïve High-Grade Non-Muscle Invasive Bladder Cancer

Treatment:
Biological Response Modifier
Chemotherapy: Local

SWOG-S1605

Trial Leaders:
Siamak Daneshmand

Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Treatment:
Biological Response Modifier
Chemotherapy: Local

SWOG-S1613

Trial Leaders:
Heinz Josef Lenz

A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) with HER-2 Amplification

Treatment:
Chemotherapy: Systemic
Immunotherapy

Phase I trials for all solid tumors:


0C-11-3

Trial Leaders:
Anthony El-Khoueiry

A First-In-Human Phase I Study of sEphB4-HSA in Patients with Advanced Solid Tumors with Expansion at the Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D).

Treatment:
Anti-Angiogenesis

0C-12-3

Trial Leaders:
Heinz Josef Lenz

Phase I Trial of Oral 5-Fluoro-2’-Deoxycytidine With Oral Tetrahydrouridine in Patients With Advanced Solid Tumors.

Treatment:
Chemotherapy: Systemic

0C-14-10

Trial Leaders:
Anthony El-Khoueiry

A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 under Adaptable Dosing Schedules in Patients with Advanced Solid Malignancies

Treatment:
Chemotherapy: Local

0C-14-9

Trial Leaders:
Anthony El-Khoueiry

A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD6738 in combination with Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients with Advanced Solid Malignancies

Treatment:
Chemotherapy: Systemic

0C-15-3

Trial Leaders:
Anthony El-Khoueiry

PhI-76 Phase I Study of TRC102 in Combination with Cisplatin and Pemetrexed in Patients with Advanced Solid Tumors, with Expansion Cohort in Mesothelioma / Phase II Study of TRC102 with Pemetrexed in Patients Refractory to Cisplatin and Pemetrexed

Treatment:
Chemotherapy: Systemic

0C-16-3

Trial Leaders:
Heinz Josef Lenz

An Open-Label, Non-Randomized, Multicenter Phase I Study to Determine the Maximum Tolerated or Recommended Phase II Dose of Oral Mutant IDH1 Inhibitor BAY 1436032 and to Characterize its Safety, Tolerability, Pharmacokinetics and Preliminary Pharmacodynamic and Anti-Tumor Activity in Patients with IDH1-R132X-Mutant Advanced Solid Tumors

Treatment:
Chemotherapy: Systemic

0C-16-6

Trial Leaders:
Anthony El-Khoueiry

PhI-87 Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors

Treatment:
Chemotherapy: Systemic

0C-16-7

Trial Leaders:
Anthony El-Khoueiry

An Open-label, Dose-finding and Proof of Concept Study for Probody™ therapeutics (probody tx) in Subjects with Metastatic or Locally Advanced Unresectable Solid Tumors and/or Lymphomas

Treatment:
Immunotherapy
Other

0C-16-8

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects with Advanced Refractory Cancers

Treatment:
Chemotherapy: Local

0C-17-1

Trial Leaders:
Anthony El-Khoueiry

Phase 1 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of CBT-101 in Subjects with Advanced Solid Tumors and c-Met Dysregulation

Treatment:
Other

0C-17-11

Trial Leaders:
Diana Hanna

Phase 1 trial of ZW25 in patients with locally advanced (unresectable) and/or metastatic HER2-expressing cancers

Treatment:
Other

0C-17-12

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2a Study of BMS-986242 Administered in Combination with Nivolumab (BMS--936558, Anti-PD-1) in Advanced Malignant Tumors

Treatment:
Immunotherapy

0C-17-14

Trial Leaders:
Anthony El-Khoueiry

An Open-Label, Non-Randomized, Multicenter Study to Determine the Pharmacokinetics and Safety of Niraparib Following a Single Oral Dose in Patients with Advanced Solid Tumors and Either Normal Hepatic Function or Moderate Hepatic Impairment

Treatment:
Chemotherapy: Systemic

0C-17-15

Trial Leaders:
Anthony El-Khoueiry

A multicenter, open-label, phase 1b/2 study to evaluate safety and efficacy of avelumab (MSB0010718C) in combination with chemotherapy with or without other anti-cancer immunotherapies as first-line treatment in patients with advanced malignancies

Treatment:
Chemotherapy: Systemic

0C-17-17

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2 First-in-human Study of BMS-986258 Alone and in Combination with Nivolumab in Advanced Malignant Tumors

Treatment:
Immunotherapy

0C-17-3

Trial Leaders:
Anthony El-Khoueiry

A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors

Treatment:
Chemotherapy: Systemic

0S-08-9

Trial Leaders:
David Quinn

Short-Term Fasting Prior to Platinum-Based Chemotherapy: Feasibility and Impact on Toxicity.

Treatment:
Chemotherapy: Systemic

0S-14-9

Trial Leaders:
Heinz Josef Lenz

A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination with Nivolumab in Select Advanced Cancers

Treatment:
Chemotherapy: Systemic
Immunotherapy

0S-16-14

Trial Leaders:
David Quinn

A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial Cancer and Other Malignant Solid Tumors that Express Nectin-4

Treatment:
Biological Response Modifier

7H-16-1

Trial Leaders:
Jorge Nieva

A Phase 1b/2, Open-Label, Multicenter Study Assessing the Safety, Tolerability, Pharmacokinetic and Preliminary Anti-tumour Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination With MEDI4736 as Second Line Treatment in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

Treatment:
Immunotherapy

CTSU-EAY131

Trial Leaders:
Heinz Josef Lenz

Molecular Analysis for Therapy Choice (MATCH)

Treatment:
(No treatments specified)

Trials which are NOT treatments of disease. Specimens or information may be collected:


0S-04-7

Trial Leaders:
Michael Press

USC Tumor and Tissue Bank.


0S-11-5

Trial Leaders:
Amir Goldkorn

Circulating Tumor Cell Collection from Cancer Patients.


0S-12-3

Trial Leaders:
Peter Conti

18F-FMAU for Imaging in Cancer Patients.


0S-12-4

Trial Leaders:
Stephen Gruber

USC Norris Comprehensive Cancer Center - Cancer Genetics Registry.


0S-15-12

Trial Leaders:
Stephen Gruber

Norris ORIEN Total Cancer Care Protocol: A Lifetime Partnership with Patients.


0S-15-15

Trial Leaders:
Patrick Williams

Are Last Impressions Lasting Impressions? Intervention of Ringing a Bell at the End of Cancer Treatment


0S-15-16

Trial Leaders:
Akil Merchant

Protocol for Immunology Specimen Collection from Cancer Patients, Patients with Hematologic Diagnoses, and Healthy Normal Controls


0S-15-17

Trial Leaders:
Patrick Williams

Patient Perceptions of Side Effects of Cancer Chemoradiotherapy


0S-15-7

Trial Leaders:
Irene Woo

Long Term Effects of Tyrosine Kinase Inhibitors on Ovarian Reserve and Fertility-A pilot study,A Pilot Study


0S-16-1

Trial Leaders:
Shannon Mumenthaler

Characterization of Mechanical Tissue Properties in Pancreas, Liver and Colon


0S-16-9

Trial Leaders:
Ebrahim Zandi

The Role of Microbiome in Cancer Therapy


0S-17-7

Trial Leaders:
Thomas A  Buchanan

The use of social media listening for targeted recruitment of Twitter users in LA County in cancer trials compared to historic recruitment data: A mixed-methods study


0S-99-10

Trial Leaders:
Heinz Josef Lenz

Blood Collection in Patients with GI Cancer.


10M-15-3

Trial Leaders:
Kevin King

Pilot Translational Study of Sonazoid-Enhanced Ultrasonography for Sentinel Lymph Node Mapping in Cutaneous Melanoma


1B-11-1

Trial Leaders:
Julie Lang

Breast Cancer Blood Biorepository.


1B-12-6

Trial Leaders:
Jaques Van Dam

Light-Scattering Spectroscopy for the Detection of Stage II-III Breast Cancer: A Pilot Study.


1B-13-2

Trial Leaders:
Julie Lang

Core Biopsies of Breast Tumor Tissue Repository.


1B-16-3

Trial Leaders:
Mary W. Yamashita

Emerging Tools in the Detection of Breast Cancer: Comparison of Contrast Enhanced Spectral Mammography with Digital Breast Tomosynthesis to Conventional Imaging Techniques Including Contrast Enhanced Magnetic Resonance Imaging and 2D Mammography with or without Targeted Ultrasound


1B-16-4

Trial Leaders:
Linda Hovanessian

A Prospective Validation Study Of A Rapid Point-Of-Care Breath Test For Breast Cancer


1B-16-5

Trial Leaders:
Stephen Gruber

Trial of Strategies to Communicate Genetic Information to Different Ethnic and Racial Subpopulations


1B-16-7

Trial Leaders:
Min Janice Lu

Prospective Observational Study of Mobile App-Based Patient-Reported Outcomes in Advanced Breast Cancer


1B-17-2

Trial Leaders:
Joan Broderick

Symptom Tracking in Women Following Mammography


2L-10-1

Trial Leaders:
Barbara Gitlitz

Addario Lung Cancer Medical Institute (ALCMI) Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network.


2L-15-1

Trial Leaders:
Christopher Lee

Biospecimen Banking and Biomarker Validation for Lung Cancer Early Detection in Cohort Receiving Low Dose Helical Computed Tomography Screening


2L-17-1

Trial Leaders:
Pamela Ward

Liquid Biopsy Research Project


2N-16-1

Trial Leaders:
Christopher Lee

Dynamic Perfusion Computed Tomography Changes after Stereotactic Body Radiation Therapy for Localized Non-Small Cell Lung Cancer


3C-13-2

Trial Leaders:
Afsaneh Barzi

A Pilot Study of Monitoring Metastatic Colorectal Cancers with Liquid Biopsies.


3C-16-1

Trial Leaders:
Christina M. Dieli-Conwright

Feasibility of a 6-week Aerobic Exercise Program during Chemotherapy for Metastatic Colorectal Cancer


3G-07-3

Trial Leaders:
Heinz Josef Lenz

Establishing Continuous Cell Lines and Xenografts from Adult Malignant Solid Tumors and Inflammatory Bowel Disease for Biological and Pre-Clinical Therapeutic Studies.


3G-07-4

Trial Leaders:
Heinz Josef Lenz

Transcriptome-Based Microarrays as Predictors of Clinical Outcome in Patients with Metastatic and Locally Advanced Gastrointestinal Cancers.


3L-17-3

Trial Leaders:
Harshawn Malhi

The role of quantitative contrast-enhanced ultrasound in YTTRIUM-90 (90Y) radioembolization of hepatocellular carcinoma


3L-17-4

Trial Leaders:
Syma Iqbal

A 5-year Longitudinal Observational Study of the Natural History and Management of Patients with Hepatocellular Carcinoma


4B-13-1

Trial Leaders:
Siamak Daneshmand

4B-13-1 Cysview® Blue Light Cystoscopy Registry


4B-15-2

Trial Leaders:
Jacek Pinski

MDSC Clinical Assay for Cancer Detection And Monitoring in Bladder Carcinoma


4B-15-5

Trial Leaders:
Andrew Weitz

Ultrasound and Biomarker Tests of Bladder Cancer Invasiveness


4B-16-2

Trial Leaders:
David Quinn

UC-GENOME: Urothelial Cancer-GENOmic analysis to iMprove patient outcomes and rEsearch


4K-03-2

Trial Leaders:
Eila Skinner

Kidney Cancer Data and Specimen Collection Project.


4K-14-4

Trial Leaders:
Jacek Pinski

MDSC Clinical Assay for Cancer Detection and Monitoring in Renal Cell Carcinoma


4P-01-2

Trial Leaders:
Eila Skinner

Prostate Cancer Prostatectomy Data and Specimen Collection Project.


4P-11-4

Trial Leaders:
Mitchell Gross

Multi-Dimensional Assessment of Circulating Tumor Cells in Patients Treated For Metastatic Prostate Cancer.


4P-12-3

Trial Leaders:
Alan Epstein

MDSC Clinical Assay for Cancer Detection and Monitoring in Prostate Cancer.


4P-15-4

Trial Leaders:
Jacek Pinski

Studies of Cell-Free DNA and RNA in Blood from Patients Being Treated for Prostate Cancer


4P-16-3

Trial Leaders:
Hossein Jadvar

Pilot Feasibility Study of 18f-FMAU PET for Diagnosing and Characterizing Prostate Cancer


4P-16-7

Trial Leaders:
Inderbir Gill

Diagnosing Clinically Significant Prostate Cancer in African American and White Men Phase II, Randomized Clinical Trial, Multi-Center, MR-guided vs. 12-core Systematic Random Biopsy, Localized Prostate Cancer


4P-17-4

Trial Leaders:
Siamak Daneshmand

Prospective Validation of Prostate Biomarkers for Repeat Biopsy: The PRIORITY Study


4P-17-8

Trial Leaders:
Jonathan Katz

Metabolic profiling of peripheral blood mononuclear cells (PBMCs) by LC-MS in prostate cancer patients


5GYN-10-3

Trial Leaders:
Lynda Roman

Banking Tissues from Normal and Disease-Related Gynecologic Surgeries.


6B-16-1

Trial Leaders:
Alexander Lerner

Evaluation of Regional Gadolinium Retention in the Brain using QSM with Correlation To Regional DCE MRI Permeability using GOCART Technique in Intracranial Neoplasm Patients Receiving Gadobenate Dimeglumine (MultiHance) or Gadoterate Meglumine (Dotarem)


6CNS-07-1

Trial Leaders:
Thomas Chen

Establishment of USC CNS and Spine Tumor Bank.


7H-16-2

Trial Leaders:
Mark Shiroishi

A Pilot Study of Whole-Neck CT Perfusion with the Toshiba Aquilion One Vision-320 Detector Row CT Scanner For Use In Head & Neck Tumor Patients


9L-10-3

Trial Leaders:
Preet Chaudhary

Comprehensive Hematology Tissue Repository (BANK).


9L-16-10

Trial Leaders:
Houda Alachkar

Characterization of T-cell Repertoire in Patients with AML undergoing HSCT through Next-Generation Sequencing of TCRA and TCRB Genes


CTSU-A151216

Trial Leaders:
Jorge Nieva

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)


CTSU/NRG-BR005

Trial Leaders:
Julie Lang

A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment without Surgery


NC-HEM-05-4

Trial Leaders:
Casey O'Connell

Hematology Database


NC-HEM-16-1

Trial Leaders:
Howard Liebman

A Phase 1/2 Open-Label, Dose Escalation Study of PRTX-100 in Adult Patients with Persistent/Chronic Immune Thrombocytopenia


NC-HEM-16-6

Trial Leaders:
Caroline Piatek

Single Arm Study of Alxn1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome (AHUS-311)


NC-HEM-17-2

Trial Leaders:
Howard Liebman

A Phase 1b, Multicenter, Open-Label, Safety, Tolerability, and Activity Study of SYNT001 in Subjects with Chronic, Stable Warm Autoimmune Hemolytic Anemia (WAIHA)